UBLCP1 activators encompass a diverse array of chemical compounds that enhance its functional activity through various signaling pathways and cellular processes. The activation of adenylate cyclase by certain molecules raises intracellular cAMP levels, which in turn activates protein kinase A (PKA). PKA is known to phosphorylate a wide range of substrates and could influence UBLCP1, a phosphatase, by altering its substrate availability or modifying its regulatory subunits, thus indirectly increasing UBLCP1 activity. In a similar vein, substances that hinder the breakdown of cAMP or those that mimic its action can also augment PKA activity, thereby potentially affecting UBLCP1's phosphatase activity. Some activators function by inhibiting protein phosphatases such as PP1 and PP2A. This inhibition can shift the cellular phosphoprotein equilibrium, potentially resulting in an indirect enhancement of UBLCP1 activity due to changes in the phosphorylation states of proteins that interact with or regulate UBLCP1.
Other activators target different kinases or phosphatases, modulating signaling cascades that UBLCP1 might be involved in. For instance, the inhibition of Syk kinase or GSK-3 can lead to alterations in downstream signaling pathways, which could indirectly heighten the activity of UBLCP1. Additionally, certain kinase inhibitors can impact kinase-dependent signaling pathways, possibly resulting in increased UBLCP1 activity through a compensatory mechanism or by alteration of its interaction network. Conversely, direct activation of protein kinase C (PKC) through specific molecules could stimulate pathways that ultimately lead to an upregulation of UBLCP1 activity. These pathways often involve complex signaling cascades, and the net effect of PKC activation could be the amplification of signals that converge on UBLCP1. Lastly, molecules that activate specific cell surface receptors influence intracellular signaling networks, which may include pathways directly or indirectly involving UBLCP1, thus potentially facilitating its activation.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $76.00 $150.00 $725.00 $1385.00 $2050.00 | 73 | |
Activates adenylate cyclase, increasing cAMP levels. UBLCP1 is a phosphatase that may be regulated by PKA, which is activated by cAMP. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $159.00 $315.00 $598.00 | 34 | |
Non-specific inhibitor of phosphodiesterases, prevents cAMP degradation, potentially enhancing PKA activity and UBLCP1 regulation. | ||||||
Dibutyryl-cAMP | 16980-89-5 | sc-201567 sc-201567A sc-201567B sc-201567C | 20 mg 100 mg 500 mg 10 g | $45.00 $130.00 $480.00 $4450.00 | 74 | |
Membrane-permeable cAMP analog that activates PKA, possibly influencing UBLCP1 activity through phosphorylation events. | ||||||
Okadaic Acid | 78111-17-8 | sc-3513 sc-3513A sc-3513B | 25 µg 100 µg 1 mg | $285.00 $520.00 $1300.00 | 78 | |
Inhibitor of protein phosphatases PP1 and PP2A, which could alter UBLCP1 activity by changing the phosphoprotein landscape. | ||||||
Calyculin A | 101932-71-2 | sc-24000 sc-24000A | 10 µg 100 µg | $160.00 $750.00 | 59 | |
Inhibits protein phosphatases like Okadaic Acid, potentially modifying UBLCP1 activity through indirect regulation of substrates. | ||||||
Cantharidin | 56-25-7 | sc-201321 sc-201321A | 25 mg 100 mg | $81.00 $260.00 | 6 | |
Inhibits protein phosphatases PP1 and PP2A, possibly affecting UBLCP1 activity by altering the balance of phosphatase activities. | ||||||
Piceatannol | 10083-24-6 | sc-200610 sc-200610A sc-200610B | 1 mg 5 mg 25 mg | $50.00 $70.00 $195.00 | 11 | |
Inhibits Syk kinase, potentially modifying signaling pathways that UBLCP1 is involved in, leading to increased UBLCP1 activity. | ||||||
Lithium | 7439-93-2 | sc-252954 | 50 g | $214.00 | ||
Inhibits GSK-3, which may impact pathways regulating UBLCP1, leading to enhanced activity of UBLCP1. | ||||||
Bisindolylmaleimide I (GF 109203X) | 133052-90-1 | sc-24003A sc-24003 | 1 mg 5 mg | $103.00 $237.00 | 36 | |
PKC inhibitor, could alter PKC-mediated signaling pathways that affect UBLCP1 activity. | ||||||
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
Broad-spectrum kinase inhibitor, could modify kinase-dependent signaling pathways involved in UBLCP1 regulation. | ||||||